Literature DB >> 12880

Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects.

J Mehta, J N Cohn.   

Abstract

Labetalol was administered to six hypertensive subjects in increasing doses for seven days. A decrease in both supine and standing arterial pressure and heart rate was observed with no change in cardiac output and few side effects. Exercise tolerance was unaltered by the drug, but the heart rate and arterial pressure response to exercise were significantly blunted. The infusion rate of isoproterenol required to produce tachycardia was increased sevenfold by 800 mg/day labetalol and tenfold by 1600 mg/day. More than twice the control dose of phenylephrine was required during labetalol therapy to produce a rise in diastolic arterial pressure reflex tachycardia to amyl nitrite-induced hypotension was attenuated. These studies indingina pectoris.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 12880     DOI: 10.1161/01.cir.55.2.370

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  29 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 2.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

3.  Response of the systemic pulmonary circulation to labetalol at rest and during exercise.

Authors:  R Fagard; P Lijnen; A Amery
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

4.  Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.

Authors:  D P Nicholls; J McNeill; P C O'Connor; D W Harron; W J Leahey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

5.  Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension.

Authors:  G Keusch; P Weidmann; W H Ziegler; R de Châtel; F C Reubi
Journal:  Klin Wochenschr       Date:  1980-01-02

Review 6.  Clinical pharmacokinetics of labetalol.

Authors:  J J McNeil; W J Louis
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

7.  Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.

Authors:  L H Opie; D White; J Lee; W F Lubbe
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Effects of combined alpha- and beta-blockade by labetalol in patients with coronary artery disease.

Authors:  M Condorelli; G Brevetti; M Chiariello; D Miceli; G Lavecchia; G Paudice; S Verrienti
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

9.  The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels.

Authors:  E Agabiti-Rosei; C L Alicandri; M Beschi; M Castellano; R Fariello; E Montini; M L Muiesan; G Romanelli; G Muiesan
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

10.  A review of the haemodynamic effects of labetalol in man.

Authors:  J N Cohn; J Mehta; G S Francis
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.